• Phosbind Acrylamide: Advancing Translational Phosphorylation

  2026-05-23

  Explore how Phos binding reagent (Phosbind) acrylamide enables antibody-free, mechanistically precise protein phosphorylation analysis, integrating the latest insights from neuronal signaling research. Designed for translational scientists, this article bridges mechanistic understanding with strategic guidance, highlights protocol innovations, and positions APExBIO's solution as a catalyst for impactful signaling pathway discoveries.

• β-Catenin/BCL9 Inhibition Sensitizes Tumors to Immunotherapy

  2026-05-22

  Feng et al. (2019) demonstrate that disrupting the β-catenin/BCL9 interaction overcomes immune checkpoint blockade resistance by modulating regulatory T cells within the tumor microenvironment. Their hydrocarbon-stapled peptide inhibitors represent a promising, experimentally validated strategy to enhance immunotherapy efficacy in solid tumor models.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Practical Workflow

  2026-05-22

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides reliable, fluorescence-based detection of goat IgG primaries in immunofluorescence, IHC, ELISA, and flow cytometry assays. It is not suitable for non-goat primaries or non-immunoglobulin targets, and its use should be limited to validated immunodetection workflows to ensure accurate results.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use Guide

  2026-05-21

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive, specific detection of goat immunoglobulins in ICC/IF, IHC, flow cytometry, and ELISA workflows by providing robust fluorescence-based signal amplification. It should only be applied in contexts where a goat primary antibody is used, and is not validated for detection of non-goat primaries or for use outside the specified immunodetection assays.

• Sulfaphenazole: A Precision CYP2C9 Inhibitor for Vascular Re

  2026-05-21

  Sulfaphenazole stands out as a potent, selective CYP2C9 inhibitor uniquely suited for dissecting cytochrome P450-mediated metabolism and vascular endpoints. Its dual action as an antibacterial and vascular-protective agent enables high-impact translational workflows, from endothelial function assays to ischemia-reperfusion injury models.

• Aclacinomycin A: Mechanisms, Cytotoxicity, and Research Para

  2026-05-20

  Aclacinomycin A (Aclarubicin) is an anthracycline used as a dual topoisomerase inhibitor and apoptosis inducer. Its cytotoxicity is quantifiable in major cancer cell lines, with well-documented molecular mechanisms and protocol benchmarks.

• Sulfaphenazole: Unveiling New Frontiers in Endothelial Resea

  2026-05-20

  Explore Sulfaphenazole as a gold-standard CYP2C9 inhibitor and its unique role in restoring vascular endothelial function and reducing oxidative stress. This article delivers advanced scientific insights, directly linking mechanistic findings to practical assay design.

• Syringin Targets EGFR/PI3K/Akt to Enhance Sunitinib in RCC M

  2026-05-19

  This study demonstrates that Syringin, a phenylpropanoid glycoside, inhibits renal cell carcinoma cell proliferation and overcomes sunitinib resistance by modulating the EGFR/PI3K/Akt pathway. The findings highlight new strategies for bioactive compound screening and natural product research in drug-resistant RCC.

• Uridine, Trisodium Salt in RNA-Mediated Genome Engineering

  2026-05-19

  Uridine, Trisodium Salt empowers next-generation RNA biosynthesis and genome editing workflows by providing unmatched purity and solubility, crucial for robust, high-fidelity assays. Its application in PRINT and related RNA-guided systems sets a new benchmark for efficiency and safety in molecular biology research.

• Reliable Autophagy Inhibition with MRT68921 Dual ULK1/2 Inhi

  2026-05-18

  This article addresses practical challenges in autophagy research, guiding biomedical scientists through experimental bottlenecks and data interpretation using MRT68921 dual autophagy kinase ULK1/2 inhibitor (SKU B6174). We highlight the reagent’s nanomolar potency, validated mechanistic selectivity, and protocol integration for robust cell viability and autophagy assays.

• Syringin Enhances Sunitinib Response in RCC via EGFR/PI3K/Ak

  2026-05-18

  This study demonstrates that Syringin, a plant-derived bioactive compound, inhibits renal cell carcinoma (RCC) cell growth and enhances the efficacy of sunitinib by targeting the EGFR/PI3K/Akt pathway. The findings highlight the mechanism by which Syringin can overcome drug resistance in RCC, offering practical pathways for natural product-based research.

• Superoxide Dismutase Activity Assay Kit: Precision in ROS Re

  2026-05-17

  Unlock robust, reproducible quantification of antioxidative enzyme activity with the Superoxide Dismutase (SOD) Activity Assay Kit from APExBIO. This kit redefines oxidative stress workflows, offering rapid, high-sensitivity detection of SOD activity across diverse disease models while minimizing assay interference.

• Ginsenoside Rg6 Reverses Cisplatin Resistance in Ovarian Can

  2026-05-16

  This study demonstrates that Ginsenoside Rg6 can sensitize cisplatin-resistant epithelial ovarian cancer cells by suppressing protein fucosylation and inducing autophagy. The findings highlight the potential of targeting glycosylation and autophagic pathways to overcome chemoresistance in ovarian cancer.

• a-MSH, amide: Advanced Mechanistic Insights in Pigmentation

  2026-05-15

  Explore the multifaceted role of a-MSH, amide in pigmentation regulation research, including its molecular mechanisms, assay optimization, and comparison with emerging anti-melanogenic agents. This cornerstone article provides deep scientific insight and practical guidance for advanced pigmentation and inflammation studies.

• Ruxolitinib (INCB018424) in Functional Immunomodulation Assa

  2026-05-15

  Explore how Ruxolitinib (INCB018424) advances functional immunomodulation assays through ATP-competitive JAK-STAT inhibition. This article uniquely bridges mechanistic selectivity with practical assay design, offering new insight for myeloproliferative disorder and oncogenic JAK2 fusion protein research.

16213 records 1/1081 page Next 12345 下5页 Last page